Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

Core Insights - Rakovina Therapeutics presented a second scientific abstract at the 2025 Society for Neuro-Oncology Annual Meeting, focusing on AI-enabled drug discovery for cancer therapies [1][5] - The research highlights the development of novel CNS-penetrating PARP1-selective inhibitors through collaboration with the Vancouver Prostate Centre and the University of British Columbia [2][5] Group 1: Research and Development - The poster presentation detailed the application of AI methods, specifically Deep Docking™ and generative-AI computational approaches, to screen chemical libraries for PARP1-selective small-molecule drug candidates [3][4] - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and favorable pharmacokinetic profiles [4][5] Group 2: Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, utilizing unique technologies for targeting DNA-damage response powered by AI [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]